CA2304869A1 - Traitement medical au moyen d'acide urique ou de precurseurs connexes - Google Patents

Traitement medical au moyen d'acide urique ou de precurseurs connexes Download PDF

Info

Publication number
CA2304869A1
CA2304869A1 CA002304869A CA2304869A CA2304869A1 CA 2304869 A1 CA2304869 A1 CA 2304869A1 CA 002304869 A CA002304869 A CA 002304869A CA 2304869 A CA2304869 A CA 2304869A CA 2304869 A1 CA2304869 A1 CA 2304869A1
Authority
CA
Canada
Prior art keywords
uric acid
cancer
precursor
acid
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304869A
Other languages
English (en)
Inventor
Roman Rozencwaig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002304869A priority Critical patent/CA2304869A1/fr
Priority to CA002405591A priority patent/CA2405591A1/fr
Priority to AU2001248173A priority patent/AU2001248173A1/en
Priority to PCT/CA2001/000457 priority patent/WO2001076606A2/fr
Publication of CA2304869A1 publication Critical patent/CA2304869A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002304869A 2000-04-07 2000-04-07 Traitement medical au moyen d'acide urique ou de precurseurs connexes Abandoned CA2304869A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002304869A CA2304869A1 (fr) 2000-04-07 2000-04-07 Traitement medical au moyen d'acide urique ou de precurseurs connexes
CA002405591A CA2405591A1 (fr) 2000-04-07 2001-04-04 Utilisation d'acide urique ou de precurseurs de celui-ci comme traitement du cancer, du sida et analogue
AU2001248173A AU2001248173A1 (en) 2000-04-07 2001-04-04 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
PCT/CA2001/000457 WO2001076606A2 (fr) 2000-04-07 2001-04-04 Utilisation d'acide urique ou de precurseurs de celui-ci comme traitement du cancer, du sida et analogue

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002304869A CA2304869A1 (fr) 2000-04-07 2000-04-07 Traitement medical au moyen d'acide urique ou de precurseurs connexes

Publications (1)

Publication Number Publication Date
CA2304869A1 true CA2304869A1 (fr) 2001-10-07

Family

ID=4165836

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304869A Abandoned CA2304869A1 (fr) 2000-04-07 2000-04-07 Traitement medical au moyen d'acide urique ou de precurseurs connexes

Country Status (3)

Country Link
AU (1) AU2001248173A1 (fr)
CA (1) CA2304869A1 (fr)
WO (1) WO2001076606A2 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1997039352A1 (fr) * 1996-04-15 1997-10-23 Fox Chase Cancer Center Methodes de detection de metabolites de purine
US5872124A (en) * 1996-07-31 1999-02-16 Thomas Jefferson University Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
ATE352306T1 (de) * 1998-07-31 2007-02-15 Meir S Sacks Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen

Also Published As

Publication number Publication date
WO2001076606A2 (fr) 2001-10-18
AU2001248173A1 (en) 2001-10-23
WO2001076606A3 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
CN114641293B (zh) 一种fgfr抑制剂的用途
CA3134156C (fr) Chiauranib pour le traitement du cancer du poumon a petites cellules
Campbell et al. Acute reactions to mega ascorbic acid therapy in malignant disease
CN112274507A (zh) NAT10的小分子抑制剂remodelin在制备口腔鳞癌治疗药物中的应用
WO2024088275A1 (fr) Utilisation d'un composé naphtylamide dans le traitement de tumeurs résistantes aux médicaments
CA2304869A1 (fr) Traitement medical au moyen d'acide urique ou de precurseurs connexes
CA2405591A1 (fr) Utilisation d'acide urique ou de precurseurs de celui-ci comme traitement du cancer, du sida et analogue
Kostakopoulos et al. Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors
WO2022221834A2 (fr) Méthode de traitement du cancer du poumon et du cancer du poumon non à petites cellules
CN109481687B (zh) 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合
Metzger et al. Long-term complete remission of melanoma liver metastases after intermittent intra-arterial cisplatin chemotherapy and surgery
Kudo et al. Leiomyosarcoma arising in the nasal cavity
CN106420789A (zh) 复发耐药消化道肿瘤地西他滨综合治疗方案
Ushigome et al. Efficacy and safety of preoperative chemoradiotherapy with S-1 for advanced rectal cancer: a phase II study
CN114668757B (zh) 土槿皮丙酸在制备预防和/或治疗恶性肿瘤药物中的应用
Boudinar et al. Clinico epidemiological and therapeutic profile of GIST: Oran center's experience
Seyed et al. Perianal Mucinous Adenocarcinoma Found Incidentally From Perianal Mass
Takamatsu et al. A case of metastatic carcinoid tumor of the pancreas resected by laparoscopic distal pancreatectomy
WO2024046405A1 (fr) Utilisation d'inhibiteur de kinase egfr
WO2019196621A1 (fr) Utilisation d'un composé de quinazoline dans un médicament pour le traitement de cancers avec mutation d'activation d'egfrv3
Yue et al. Tongue Squamous Cell Carcinoma in Younger Adult Female with a History of Breast Cancer: A Rare Case Report
Manal et al. Primary Hepatic Squamous Cell Carcinoma: A Case Report
Lyagoubi et al. Primary Hepatic Squamous Cell Carcinoma: A
WO2018072269A1 (fr) Application d'un médicament anti-inflammatoire non stéroïdien pour augmenter la sensibilité d'une cellule tumorale à un inhibiteur de la tyrosine kinase
Zhu et al. Effect of sequential gemcitabine and epirubicin therapy on high-risk non-muscle invasive bladder cancer following transurethral bladder tumour resection

Legal Events

Date Code Title Description
FZDE Dead